Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients.

Q3 Medicine

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2021-11-12 DOI:10.1177/24755303211056059

Felix Pavlotsky, Zvi Segal, Aviv Barzilai

{"title":"Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients.","authors":"Felix Pavlotsky, Zvi Segal, Aviv Barzilai","doi":"10.1177/24755303211056059","DOIUrl":null,"url":null,"abstract":"Background: Data regarding anti-COVID-19 vaccination efficacy in psoriasis patients treated with immune-modulatory medications are scarce.Objective: This study aims to examine the rate of positive antibody response following BNT162b2 vaccine in those patients.Methods: BNT162b2-vaccinated and immune modifier-treated psoriatic patients were assigned to serological testing of IgG antibodies to protein S of SARS-CoV-2 after the second vaccination dose by Abbott Architect or Beckman Coulter. Levels ≥ 1 S1 units/mL (S/ml) and > 150 arbitrary units/ml (AU/ml) are considered a positive antibody response, respectively. The antibody levels further analyzed according to the patient's characteristics and compared to health workers' controls.Results: Forty-nine of the 51 patients had a positive antibody response. Overall, patients treated with immune-modulatory medications had antibody levels similar to the control group.Conclusions: Immune modifier-treated psoriasis patients seem to develop a positive antibody response to the full BNT162b2 vaccination in the vast majority of cases.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"7 1","pages":"24-28"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361508/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psoriasis and Psoriatic Arthritis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24755303211056059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Data regarding anti-COVID-19 vaccination efficacy in psoriasis patients treated with immune-modulatory medications are scarce.

Objective: This study aims to examine the rate of positive antibody response following BNT162b2 vaccine in those patients.

Methods: BNT162b2-vaccinated and immune modifier-treated psoriatic patients were assigned to serological testing of IgG antibodies to protein S of SARS-CoV-2 after the second vaccination dose by Abbott Architect or Beckman Coulter. Levels ≥ 1 S1 units/mL (S/ml) and > 150 arbitrary units/ml (AU/ml) are considered a positive antibody response, respectively. The antibody levels further analyzed according to the patient's characteristics and compared to health workers' controls.

Results: Forty-nine of the 51 patients had a positive antibody response. Overall, patients treated with immune-modulatory medications had antibody levels similar to the control group.

Conclusions: Immune modifier-treated psoriasis patients seem to develop a positive antibody response to the full BNT162b2 vaccination in the vast majority of cases.

查看原文本刊更多论文

免疫调节剂治疗的银屑病患者对BNT162b2疫苗的抗体反应

背景关于免疫调节药物治疗银屑病患者抗covid -19疫苗接种效果的数据很少。目的探讨BNT162b2疫苗接种后的抗体阳性应答率。方法采用Abbott Architect或Beckman Coulter对接种bnt162b2疫苗和免疫修饰剂治疗的银屑病患者在第二次接种后进行SARS-CoV-2蛋白S抗体的血清学检测。水平≥1 S1单位/mL (S/ mL)和低于150任意单位/mL (AU/ mL)分别被认为是阳性抗体反应。根据患者的特点进一步分析抗体水平，并与卫生工作者对照进行比较。结果51例患者中49例抗体反应阳性。总的来说，接受免疫调节药物治疗的患者的抗体水平与对照组相似。结论:在绝大多数情况下，免疫修饰剂治疗的银屑病患者似乎对BNT162b2全疫苗接种产生了阳性抗体反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Psoriasis and Psoriatic Arthritis Medicine-Dermatology

CiteScore

1.30

自引率

0.00%

发文量